PL1660482T3 - Metanosulfonian 3-[(2-{[4-(heksyloksykarbonyloamino-imino-metylo)-fenyloamino]-metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-ylo-amino]-propionianu etylu i jego zastosowanie jako leku - Google Patents

Metanosulfonian 3-[(2-{[4-(heksyloksykarbonyloamino-imino-metylo)-fenyloamino]-metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-ylo-amino]-propionianu etylu i jego zastosowanie jako leku

Info

Publication number: PL1660482T3
Authority: PL; Poland
Prior art keywords: methyl; hexyloxycarbonylamino; benzimidazol; phenylamino; imino
Prior art date: 2003-08-29

Application number

PL04764411T

Other languages

English (en)

Inventor

Rainer Sobotta

Peter Sieger

Rolf Schmid

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-29

Filing date

2004-08-24

Publication date

2009-08-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34202202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1660482(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-08-24 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2009-08-31 Publication of PL1660482T3 publication Critical patent/PL1660482T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)

PL04764411T 2003-08-29 2004-08-24 Metanosulfonian 3-[(2-{[4-(heksyloksykarbonyloamino-imino-metylo)-fenyloamino]-metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-ylo-amino]-propionianu etylu i jego zastosowanie jako leku PL1660482T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE10339862A DE10339862A1 (de)	2003-08-29	2003-08-29	3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
PCT/EP2004/009432 WO2005028468A1 (de)	2003-08-29	2004-08-24	3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester -methansulfonat und dessen verwendung als arzneimittel
EP04764411A EP1660482B1 (de)	2003-08-29	2004-08-24	3-[(2-{ 4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -propionsäure-ethylester -methansulfonat und dessen verwendung als arzneimittel

Publications (1)

Publication Number	Publication Date
PL1660482T3 true PL1660482T3 (pl)	2009-08-31

Family

ID=34202202

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL09153155T PL2060569T3 (pl)	2003-08-29	2004-08-24	Hemihydrat metanosulfonianu estru etylowego kwasu 3-[(2-{[4-heksylokarbonyloamino-imino-metylo)-fenyloamino]-metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-ylo-amino]-propionowego i jego zastosowanie jako leku
PL04764411T PL1660482T3 (pl)	2003-08-29	2004-08-24	Metanosulfonian 3-[(2-{[4-(heksyloksykarbonyloamino-imino-metylo)-fenyloamino]-metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-ylo-amino]-propionianu etylu i jego zastosowanie jako leku

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL09153155T PL2060569T3 (pl)	2003-08-29	2004-08-24	Hemihydrat metanosulfonianu estru etylowego kwasu 3-[(2-{[4-heksylokarbonyloamino-imino-metylo)-fenyloamino]-metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-ylo-amino]-propionowego i jego zastosowanie jako leku

Country Status (36)

Country	Link
US (2)	US20050234104A1 (pl)
EP (2)	EP2060569B1 (pl)
JP (2)	JP5348842B2 (pl)
KR (1)	KR101331039B1 (pl)
CN (2)	CN102167695B (pl)
AR (2)	AR045520A1 (pl)
AT (2)	ATE430145T1 (pl)
AU (2)	AU2004274139B2 (pl)
BR (1)	BRPI0413849A (pl)
CA (2)	CA2749579C (pl)
CO (1)	CO5660265A2 (pl)
CY (2)	CY1109299T1 (pl)
DE (2)	DE10339862A1 (pl)
DK (2)	DK1660482T3 (pl)
EA (1)	EA009736B1 (pl)
EC (2)	ECSP066399A (pl)
ES (2)	ES2326654T3 (pl)
HK (2)	HK1096682A1 (pl)
HR (2)	HRP20090311T1 (pl)
IL (1)	IL173885A (pl)
ME (1)	ME00340B (pl)
MX (1)	MXPA06001959A (pl)
MY (2)	MY145632A (pl)
NO (2)	NO334115B1 (pl)
NZ (2)	NZ545984A (pl)
PE (1)	PE20050348A1 (pl)
PL (2)	PL2060569T3 (pl)
PT (2)	PT2060569E (pl)
RS (2)	RS53370B (pl)
SG (1)	SG145734A1 (pl)
SI (2)	SI1660482T1 (pl)
TW (2)	TWI418553B (pl)
UA (1)	UA85686C2 (pl)
UY (2)	UY28493A1 (pl)
WO (1)	WO2005028468A1 (pl)
ZA (1)	ZA200600518B (pl)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030181488A1 (en) *	2002-03-07	2003-09-25	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
US20050070537A1 (en)	2002-10-10	2005-03-31	Chris Rundfeldt	Use of dihydroimidazolones for the treatment of dogs
DE10337697A1 (de) *	2003-08-16	2005-03-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
DE102005020002A1 (de) *	2005-04-27	2006-11-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
DE102005025728A1 (de) *	2005-06-04	2006-12-07	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
DE102006054005A1 (de) *	2006-11-16	2008-05-21	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
CA2711766A1 (en) *	2008-03-28	2009-10-01	Boehringer Ingelheim International Gmbh	Process for preparing orally administered dabigatran formulations
AU2009272796A1 (en) *	2008-07-14	2010-01-21	Boehringer Ingelheim International Gmbh	Method for manufacturing medicinal compounds containing dabigatran
US20110190352A1 (en) *	2008-08-19	2011-08-04	Boehringer Ingelheim International Gmbh	Use of dabigatranetexilate for treating patients with pulmonary hypertension
KR20110086700A (ko)	2008-11-11	2011-07-29	베링거 인겔하임 인터내셔날 게엠베하	통상의 와파린 요법에 비해 안전성 프로파일이 향상된 다비가트란 에텍실레이트 또는 이의 염을 사용하여 혈전증을 치료하거나 예방하는 방법
US20120142703A1 (en)	2009-05-14	2012-06-07	Boehringer Ingelheim International Gmbh	New combination therapy in treatment of oncological and fibrotic diseases
HUP1000069A2 (en) *	2010-02-02	2012-05-02	Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag	New salts for the preparation of pharmaceutical composition
PT2542224E (pt) *	2010-03-01	2014-10-03	Ratiopharm Gmbh	Composição farmacêutica oral que contém etexilato de dabigatrana
EA201201263A1 (ru)	2010-03-08	2013-04-30	Рациофарм Гмбх	Фармацевтическая композиция, содержащая этексилат дабигатрана
EP2588090B2 (en)	2010-07-01	2023-11-22	KRKA, tovarna zdravil, d.d., Novo mesto	Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts
WO2012027543A1 (en)	2010-08-25	2012-03-01	Teva Pharmaceuticals Usa, Inc.	Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof
HUE026408T2 (en)	2010-09-27	2016-06-28	Ratiopharm Gmbh	Dabigatran etexylate bis-mesylate salt, solid forms and process for their preparation
WO2012077136A2 (en) *	2010-12-06	2012-06-14	Msn Laboratories Limited	Process for the preparation of benzimidazole derivatives and its salts
HUP1100244A2 (hu)	2011-05-11	2012-11-28	Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag	Gyógyszeripari intermedierek és eljárás elõállításukra
WO2012162492A1 (en)	2011-05-24	2012-11-29	Teva Pharmaceutical Industries Ltd.	Compressed core comprising organic acids for a pharmaceutical composition
EP2793864A1 (en)	2011-12-22	2014-10-29	Boehringer Ingelheim International GmbH	Immediate release multi unit pellet system
WO2013111163A2 (en)	2012-01-20	2013-08-01	Cadila Healthcare Limited	Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof
EP2806858A1 (en)	2012-01-24	2014-12-03	Boehringer Ingelheim International Gmbh	Novel orally administered dabigatran formulation
JO3616B1 (ar)	2012-02-21	2020-08-27	Esteve Pharmaceuticals Sa	تركيبات دوائية من إيتيكسيلات دابيجاتران تعطى بالفم
EP2631234A1 (en)	2012-02-23	2013-08-28	Esteve Química, S.A.	Solid forms of dabigatran etexilate mesylate and processes for their preparation
WO2013144971A1 (en)	2012-03-27	2013-10-03	Cadila Healthcare Limited	New solid forms of dabigatran etexilate bisulfate and mesylate and processes to prepare them
EP2834224B1 (en)	2012-04-02	2018-06-06	MSN Laboratories Limited	Process for the preparation of benzimidazole derivatives and salts thereof
JP2015522596A (ja) *	2012-07-16	2015-08-06	インテルキム、ソシエダッドアノニマ	ダビガトランエテキシラートの合成のための中間体を調製する方法及び該中間体の結晶形
US9150542B2 (en)	2012-08-31	2015-10-06	Ranbaxy Laboratories Limited	Process for the preparation of crystalline form I of methanesulfonate salt of dabigatran etexilate
CN103664882A (zh) *	2012-09-20	2014-03-26	天津药物研究院	结晶变体形态的达比加群酯及其制备方法和用途
CN103864756B (zh) *	2012-12-11	2018-06-15	四川海思科制药有限公司	丁二磺酸达比加群酯及其制备方法和用途
EP2835370A1 (en)	2013-08-08	2015-02-11	Medichem, S.A.	New crystals of dabigatran etexilate mesylate
CN104418840A (zh) *	2013-09-05	2015-03-18	天津汉瑞药业有限公司	甲磺酸达比加群酯无水化合物
WO2015128875A2 (en)	2014-02-26	2015-09-03	Megafine Pharma (P) Ltd.	A process for preparation of dabigatran etexilate mesylate and intermediates thereof
CN104892574A (zh)	2014-03-04	2015-09-09	浙江海正药业股份有限公司	达比加群酯甲磺酸盐的晶型及其制备方法和用途
US9820988B2 (en)	2014-03-24	2017-11-21	Boehringer Ingelheim Vetmedica Gmbh	Treatment of epileptic disorders in feline animals
CN108864049A (zh) *	2014-04-04	2018-11-23	江苏天士力帝益药业有限公司	达比加群酯甲磺酸盐新晶型及其制备方法
CN105461686A (zh) *	2014-08-25	2016-04-06	江苏豪森药业股份有限公司	制备高纯度甲磺酸达比加群酯晶型的方法
CN104825422B (zh) *	2014-09-29	2017-12-12	普济生物科技（台州）有限公司	含达比加群酯甲磺酸盐的药物组合物及其制备方法
EP4205743A1 (en)	2014-12-31	2023-07-05	Shenzhen Pharmacin Co., Ltd.	Pharmaceutical composition and preparation method therefor
CN104725360A (zh) *	2015-04-09	2015-06-24	重庆东得医药科技有限公司	一种甲磺酸达比加群酯ⅰ晶型的制备方法
WO2017111637A1 (en)	2015-12-23	2017-06-29	Zaklady Farmaceutyczne Polpharma Sa	Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof
US10449195B2 (en)	2016-03-29	2019-10-22	Shenzhen Pharmacin Co., Ltd.	Pharmaceutical formulation of palbociclib and a preparation method thereof
CN107778291A (zh) *	2016-08-31	2018-03-09	亚宝药业集团股份有限公司	一种甲磺酸达比加群酯晶型ⅱ的制备方法
EP3873916B8 (en)	2018-10-29	2025-03-26	Shanghai Synergy Pharmaceutical Sciences, Ltd.	Novel dipeptide compounds and uses thereof
JP2020193184A (ja) *	2019-05-30	2020-12-03	ダイト株式会社	ダビガトランエテキシラートメタンスルホン酸塩の形態ｉの製造方法
EP3771465A1 (en)	2019-08-01	2021-02-03	Zaklady Farmaceutyczne Polpharma SA	Pharmaceutical composition comprising dabigatran etexilate
CN114306245A (zh)	2020-09-29	2022-04-12	深圳市药欣生物科技有限公司	无定形固体分散体的药物组合物及其制备方法
CN114380793B (zh) *	2020-10-20	2024-02-23	北京澳合药物研究院有限公司	一种甲磺酸达比加群酯晶型i的制备方法及其应用
US11446286B1 (en) *	2022-02-28	2022-09-20	King Faisal University	Treatment of fungal infections using dabigatran etexilate

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6087380A (en) *	1949-11-24	2000-07-11	Boehringer Ingelheim Pharma Kg	Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
US4427468A (en) *	1976-01-16	1984-01-24	Her Majesty The Queen In Right Of Canada	Curable propellant binding systems with bonding agent combination
DE3000979A1 (de) *	1980-01-12	1981-07-23	Dr. Karl Thomae Gmbh, 7950 Biberach	Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
DE3124090A1 (de) *	1981-06-19	1983-01-05	Dr. Karl Thomae Gmbh, 7950 Biberach	Neue orale dipyridamolformen
DE3126703A1 (de) *	1981-07-07	1983-01-27	Dr. Karl Thomae Gmbh, 7950 Biberach	Bromhexin-retardform und verfahren zu ihrer herstellung
JPS58134033A (ja)	1982-02-02	1983-08-10	Fujisawa Pharmaceut Co Ltd	医薬組成物
US4675405A (en) *	1984-09-21	1987-06-23	American Home Products Corporation	Quinoline compounds as antiallergic and antithrombotic agents
DE4129603A1 (de) *	1991-09-06	1993-03-11	Thomae Gmbh Dr K	Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5416099A (en) *	1991-10-29	1995-05-16	Merck & Co., Inc.	Fibrinogen receptor antagonists
ZA928276B (en)	1991-10-31	1993-05-06	Daiichi Seiyaku Co	Aromatic amidine derivates and salts thereof.
DE69331906T2 (de) *	1992-08-05	2002-12-19	F.H. Faulding & Co. Ltd., Underdale	Granulierte pharmazeutische zusammensetzung
JPH06340619A (ja)	1993-05-03	1994-12-13	Bristol Myers Squibb Co	グアニジニルまたはアミジニル置換メチルアミノ複素環トロンビン抑制剤
CA2134192A1 (en)	1993-11-12	1995-05-13	Michael L. Denney	5, 6-bicyclic glycoprotein iib/iiia antagonists
PE121699A1 (es)	1997-02-18	1999-12-08	Boehringer Ingelheim Pharma	Heterociclos biciclicos disustituidos como inhibidores de la trombina
US6414008B1 (en) *	1997-04-29	2002-07-02	Boehringer Ingelheim Pharma Kg	Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
DE19752843C2 (de)	1997-11-28	2003-01-09	Byk Gulden Lomberg Chem Fab	Arzneimittelzubereitung in Tabletten- oder Pelletform für Pantoprazol und Omeprazol
DE10133786A1 (de)	2001-07-16	2003-02-06	Boehringer Ingelheim Pharma	Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis
US6627646B2 (en) *	2001-07-17	2003-09-30	Sepracor Inc.	Norastemizole polymorphs
NZ546367A (en) *	2002-03-07	2008-08-29	Boehringer Ingelheim Pharma	Methanesulphonate salt of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionate to be administered orally
DE10245624A1 (de) *	2002-09-30	2004-04-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2yl-amino]-propinsäure-ethylester und dessen Salze
DE10209982A1 (de) *	2002-03-07	2003-09-25	Boehringer Ingelheim Pharma	Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
US20030181488A1 (en) *	2002-03-07	2003-09-25	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10235639A1 (de) *	2002-08-02	2004-02-19	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel
EP2062580A1 (en) *	2003-04-24	2009-05-27	Boehringer Ingelheim International GmbH	Use of dipyridamole or mopidamole for treatment and prevention of thromboembolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of trombin receptors
DE10337697A1 (de) *	2003-08-16	2005-03-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
US20050107438A1 (en) *	2003-09-03	2005-05-19	Boehringer Ingelheim International Gmbh	Pharmaceutical composition comprising 3-[(2-{[4-(Hexyloxycarbonylaminoiminomethyl) phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester or a salt therefore
EP1609784A1 (de) *	2004-06-25	2005-12-28	Boehringer Ingelheim Pharma GmbH & Co.KG	Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen
US20060222640A1 (en) *	2005-03-29	2006-10-05	Boehringer Ingelheim International Gmbh	New pharmaceutical compositions for treatment of thrombosis
DE102005020002A1 (de) *	2005-04-27	2006-11-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
DE102005025728A1 (de) *	2005-06-04	2006-12-07	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
DE102005061623A1 (de) *	2005-12-21	2007-06-28	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen
DE102005061624A1 (de) *	2005-12-21	2007-06-28	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verbessertes Verfahren zur Herstellung von Salzen von 4-(Benzimidazolylmethylamino)-Benzamidinen

2003
- 2003-08-29 DE DE10339862A patent/DE10339862A1/de not_active Withdrawn
2004
- 2004-08-13 US US10/918,017 patent/US20050234104A1/en not_active Abandoned
- 2004-08-24 CA CA2749579A patent/CA2749579C/en not_active Expired - Lifetime
- 2004-08-24 KR KR1020067003994A patent/KR101331039B1/ko active IP Right Grant
- 2004-08-24 AT AT04764411T patent/ATE430145T1/de active
- 2004-08-24 PT PT09153155T patent/PT2060569E/pt unknown
- 2004-08-24 ES ES04764411T patent/ES2326654T3/es not_active Expired - Lifetime
- 2004-08-24 ME MEP-2008-506A patent/ME00340B/me unknown
- 2004-08-24 BR BRPI0413849-0A patent/BRPI0413849A/pt not_active Application Discontinuation
- 2004-08-24 UA UAA200603253A patent/UA85686C2/ru unknown
- 2004-08-24 SI SI200431177T patent/SI1660482T1/sl unknown
- 2004-08-24 CA CA2537054A patent/CA2537054C/en not_active Expired - Lifetime
- 2004-08-24 NZ NZ545984A patent/NZ545984A/en not_active IP Right Cessation
- 2004-08-24 RS RS20060136A patent/RS53370B/en unknown
- 2004-08-24 RS YUP-2006/0136A patent/RS20060136A/sr unknown
- 2004-08-24 PL PL09153155T patent/PL2060569T3/pl unknown
- 2004-08-24 ES ES09153155T patent/ES2375896T3/es not_active Expired - Lifetime
- 2004-08-24 DK DK04764411T patent/DK1660482T3/da active
- 2004-08-24 NZ NZ578586A patent/NZ578586A/en not_active IP Right Cessation
- 2004-08-24 EP EP09153155A patent/EP2060569B1/de not_active Revoked
- 2004-08-24 JP JP2006524316A patent/JP5348842B2/ja not_active Expired - Lifetime
- 2004-08-24 PL PL04764411T patent/PL1660482T3/pl unknown
- 2004-08-24 SI SI200431794T patent/SI2060569T1/sl unknown
- 2004-08-24 SG SG200805933-9A patent/SG145734A1/en unknown
- 2004-08-24 AT AT09153155T patent/ATE529420T1/de active
- 2004-08-24 MX MXPA06001959A patent/MXPA06001959A/es active IP Right Grant
- 2004-08-24 CN CN2011100536316A patent/CN102167695B/zh not_active Expired - Lifetime
- 2004-08-24 DE DE502004009431T patent/DE502004009431D1/de not_active Expired - Lifetime
- 2004-08-24 EP EP04764411A patent/EP1660482B1/de not_active Expired - Lifetime
- 2004-08-24 DK DK09153155.8T patent/DK2060569T3/da active
- 2004-08-24 WO PCT/EP2004/009432 patent/WO2005028468A1/de active Application Filing
- 2004-08-24 AU AU2004274139A patent/AU2004274139B2/en not_active Expired
- 2004-08-24 PT PT04764411T patent/PT1660482E/pt unknown
- 2004-08-24 EA EA200600381A patent/EA009736B1/ru not_active IP Right Cessation
- 2004-08-24 CN CN2004800249521A patent/CN1845917B/zh not_active Expired - Lifetime
- 2004-08-26 MY MYPI20043499A patent/MY145632A/en unknown
- 2004-08-26 MY MYPI20093734A patent/MY145696A/en unknown
- 2004-08-27 TW TW100125555A patent/TWI418553B/zh not_active IP Right Cessation
- 2004-08-27 PE PE2004000824A patent/PE20050348A1/es not_active Application Discontinuation
- 2004-08-27 UY UY28493A patent/UY28493A1/es not_active Application Discontinuation
- 2004-08-27 TW TW093125929A patent/TWI375674B/zh not_active IP Right Cessation
- 2004-08-27 AR ARP040103089A patent/AR045520A1/es active Pending
2006
- 2006-01-18 ZA ZA2006/00518A patent/ZA200600518B/en unknown
- 2006-02-23 IL IL173885A patent/IL173885A/en active IP Right Grant
- 2006-02-28 CO CO06019918A patent/CO5660265A2/es not_active Application Discontinuation
- 2006-03-01 EC EC2006006399A patent/ECSP066399A/es unknown
- 2006-03-28 NO NO20061420A patent/NO334115B1/no not_active IP Right Cessation
2007
- 2007-03-15 HK HK07102805.4A patent/HK1096682A1/xx not_active IP Right Cessation
- 2007-03-15 HK HK11112042.0A patent/HK1157760A1/xx not_active IP Right Cessation
2008
- 2008-01-30 US US12/022,655 patent/US7932273B2/en active Active
2009
- 2009-05-27 HR HR20090311T patent/HRP20090311T1/xx unknown
- 2009-07-23 CY CY20091100788T patent/CY1109299T1/el unknown
- 2009-08-28 AR ARP090103316A patent/AR073225A2/es unknown
- 2009-12-18 UY UY0001032342A patent/UY32342A/es not_active Application Discontinuation
2010
- 2010-04-13 AU AU2010201457A patent/AU2010201457B2/en not_active Expired
2011
- 2011-05-09 JP JP2011104428A patent/JP5566332B2/ja not_active Expired - Lifetime
- 2011-11-21 EC EC2011006399A patent/ECSP11006399A/es unknown
2012
- 2012-01-10 HR HR20120028T patent/HRP20120028T1/hr unknown
- 2012-01-11 CY CY20121100024T patent/CY1112222T1/el unknown
2013
- 2013-06-05 NO NO20130778A patent/NO20130778L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
UA85686C2 (ru)	2009-02-25
MY145696A (en)	2012-03-30
EA009736B1 (ru)	2008-02-28
ZA200600518B (en)	2006-12-27
EP2060569A1 (de)	2009-05-20
JP2011178803A (ja)	2011-09-15
AU2010201457B2 (en)	2012-05-10
AR073225A2 (es)	2010-10-20
NO20130778L (no)	2006-03-28
ATE430145T1 (de)	2009-05-15
ECSP066399A (es)	2006-09-18
CN1845917B (zh)	2011-05-11
NO20061420L (no)	2006-03-28
US20080119523A1 (en)	2008-05-22
IL173885A (en)	2015-04-30
AU2004274139B2 (en)	2010-05-13
PL2060569T3 (pl)	2012-03-30
KR101331039B1 (ko)	2013-11-20
ECSP11006399A (es)	2011-12-30
IL173885A0 (en)	2006-07-05
JP2007504106A (ja)	2007-03-01
AR045520A1 (es)	2005-11-02
MXPA06001959A (es)	2006-05-17
CN102167695A (zh)	2011-08-31
BRPI0413849A (pt)	2006-10-24
KR20070031830A (ko)	2007-03-20
HRP20090311T1 (en)	2009-07-31
CO5660265A2 (es)	2006-07-31
CN102167695B (zh)	2013-06-19
US20050234104A1 (en)	2005-10-20
NZ578586A (en)	2011-01-28
DE502004009431D1 (en)	2009-06-10
AU2010201457A1 (en)	2010-05-06
CA2749579A1 (en)	2005-03-31
ME00340B (me)	2011-05-10
EP1660482B1 (de)	2009-04-29
PE20050348A1 (es)	2005-06-15
EP1660482A1 (de)	2006-05-31
MY145632A (en)	2012-03-15
TWI418553B (zh)	2013-12-11
SG145734A1 (en)	2008-09-29
CA2749579C (en)	2013-04-16
WO2005028468A1 (de)	2005-03-31
DE10339862A1 (de)	2005-03-24
AU2004274139A1 (en)	2005-03-31
ES2375896T3 (es)	2012-03-07
NO334115B1 (no)	2013-12-16
RS20060136A (en)	2008-06-05
NZ545984A (en)	2009-08-28
US7932273B2 (en)	2011-04-26
ES2326654T3 (es)	2009-10-16
RS53370B (en)	2014-10-31
ATE529420T1 (de)	2011-11-15
HK1157760A1 (en)	2012-07-06
UY32342A (es)	2011-07-29
TW201202217A (en)	2012-01-16
JP5566332B2 (ja)	2014-08-06
CN1845917A (zh)	2006-10-11
JP5348842B2 (ja)	2013-11-20
PT2060569E (pt)	2011-12-29
EA200600381A1 (ru)	2006-08-25
CY1109299T1 (el)	2014-07-02
DK2060569T3 (da)	2012-01-23
CA2537054A1 (en)	2005-03-31
CY1112222T1 (el)	2015-12-09
HRP20120028T1 (hr)	2012-01-31
MEP50608A (en)	2011-02-10
PT1660482E (pt)	2009-06-04
DK1660482T3 (da)	2009-08-24
CA2537054C (en)	2011-12-06
EP2060569B1 (de)	2011-10-19
TWI375674B (en)	2012-11-01
UY28493A1 (es)	2005-03-31
SI2060569T1 (sl)	2012-01-31
HK1096682A1 (pl)	2007-06-08
SI1660482T1 (sl)	2009-10-31
TW200512206A (en)	2005-04-01

Publication	Publication Date	Title
PT1660482E (pt)	2009-06-04	Metanossulfonato de 3-[(2-{4-(hexiloxicarbonilamino-iminometil)- fenilamino]-metil}-1-metil-1h-benzimidazol-5-carbonil)- piridin-2-il-amino]-propionato de etilo e a sua utilização como medicamento
PL370517A1 (pl)	2005-05-30	Doustna postać do podawania estru etylowego kwasu3-[(2-{[4-(heksylooksykarbonyloaminoiminometylo)-fenyloamino]metylo}-1-metylo-1H-benzimidazolo-5-karbonylo)-pirydyn-2-yloamino]propionowego i jego soli
IL211491A0 (en)	2011-05-31	4-(benzimidazolylmethylamino)-benzamidines
AU157458S (en)	2005-02-02	A portable media player
ZA200609136B (en)	2008-07-30	4-Hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide
GB0711295D0 (en)	2007-07-18	A method of automatic computer controlled reading of a publication
IL187845A0 (en)	2008-03-20	Polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-iminomethyl)
PT1658056E (pt)	2008-06-23	Comprimido contendo 3-[(2-{[4-(hexiloxicarbonilamino-iminometil)- fenilamino]-metil}-1-metil-1h-benzimidazol-5-carbonil)- piridin-2-il-amino]-propionato de etilo ou os seus sais
AU157457S (en)	2005-02-02	A media player
GB0407389D0 (en)	2004-05-05	Information retrieval
GB0407816D0 (en)	2004-05-12	Information retrieval
HK1101758A1 (zh)	2007-10-26	苯氧基烷基硫基 -苯氧基乙酸及類似物
HK1104523A1 (en)	2008-01-18	4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs 4-(())-
GB2419090B (en)	2008-04-02	A nail clipper
EP1708852A4 (en)	2008-09-03	BRAND MANAGEMENT
PL1705998T3 (pl)	2014-10-31	Zastosowanie karboksypeptydazy
HK1111514A1 (en)	2008-08-08	A semiconductor storage apparatus with a function of displaying information when being power down
GB0409735D0 (en)	2004-06-09	Portable media player
GB0402447D0 (en)	2004-03-10	Improved adhesive tape
FR2878149B1 (fr)	2012-07-13	Cone court d'emmanchement de tetes femorales a grand debattement
GB0419546D0 (en)	2004-10-06	A cord fastener
GB0410361D0 (en)	2004-06-09	Tape dispenser
GB0418910D0 (en)	2004-09-29	Novel fastener
GB0401456D0 (en)	2004-02-25	Computer development 1